Feature | March 18, 2014

Document Addresses PCI Quality, Safety

March 18, 2014 — The increasing number of percutaneous coronary interventions (PCIs) being performed at low-volume centers without on-site cardiac surgery backup has driven the need for new safety and quality protocols. This is according to an expert consensus document written by a committee representing the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA). The document outlines steps hospitals can take to provide the safest possible environment for PCI when the facility does not provide cardiac surgery as a backup should complications occur.

"This issue was last reviewed in 2007, and since that time interventional cardiology has seen important changes," said Gregory J. Dehmer, M.D., FACC, FSCAI, director of the Division of Cardiology at Baylor Scott & White Health, Central Texas (Temple, Texas) and the document's lead author. "The new recommendations aim to increase safety while maintaining access to quality care for underserved patients."

Although PCI use increased significantly since the procedure was introduced more than 30 years ago, for a variety of reasons use peaked in 2006 and has since dropped by nearly a third. Advances in drug-eluting stents, greater use of medication to treat some types of blockages, increased emphasis on heart disease prevention, and new technologies to help physicians better evaluate blockages have all contributed to a drop in PCI use.

This drop has led to an increase in the number of facilities that are considered "low volume," or performing fewer than 200 PCIs per year, according to the consensus document. Overall, one-third of facilities performing PCI had no on-site cardiac surgery, and among those hospitals, about two-thirds were considered low volume.

The consensus document cites studies and meta-analyses since 2006 that find no indication of increased mortality or a greater need for emergency bypass surgery for either heart attack or elective PCI patients at sites without on-site cardiac surgery. In general, it said, safety questions about sites without surgical backup have diminished "in the presence of a proven, well-defined and protocol-driven approach."

However, the paper echoed an earlier joint recommendation that low-volume PCI programs "must have stringent systems and process protocols in place" with close monitoring of outcomes and strategies that encourage collaboration with higher-volume facilities.

"As the technique and equipment for PCI has improved, the evidence from randomized studies suggests that procedures can be performed safely without on-site surgery," said Dehmer. "But at the same time, the number of low-volume centers is increasing, making it essential that those facilities without backup cardiac surgery have strict protocols in place to ensure the highest level of patient safety."

The consensus document compiles the recommendations made by various organizations in several different documents into one resource for use by facilities without on-site surgery. These include a greater emphasis on quality review programs, the recommended number of procedures physicians should perform per year to maintain their skills, mentoring for newly trained cardiologists and criteria to evaluate PCI programs. It also recommends a shift in focus to system-wide planning for rational distribution of PCI services.

"The expansion of small PCI programs without on-site surgery has not substantially improved access to PCI," said Dehmer. "Although the number of facilities capable of performing PCI has increased 44 percent, the number of people who live within a one-hour drive of a PCI facility has increased only slightly. Today about 80 percent of the population is within one-hour of a PCI hospital." Recent surveys found expansion of PCI reduced drive times for just 9 percent of the population.

The document also supports the ongoing study and surveillance of all PCI programs through participation in national databases, encourages public reporting of results and acknowledges further declines in PCI volumes might necessitate the closure of some PCI programs in the future.

The consensus document, titled, "SCAI/ACCF/AHA Expert Consensus Document Update on Percutaneous Coronary Intervention without On-Site Surgical Backup," updates a 2007 consensus document. It was published online in Catheterization & Cardiovascular Interventions, Journal of the American College of Cardiology (JACC) and Circulation: Journal of the American Heart Association.

For more information: onlinelibrary.wiley.com

Related Content

Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Arterial Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
Patient Race, Gender Both Important in Predicting Heart Attack Symptoms in the ER
News | Cath Lab| July 07, 2017
Researchers at the George Washington University (GW) found that certain symptoms are more and less predictive of...
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Heartflow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

HeartFlow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

Technology | CT Angiography (CTA)| July 06, 2017
July 6, 2017 — GE Healthcare and HeartFlow Inc.
Overlay Init